Management and interpretation of novel toxicities of molecular targeted therapies: renal toxicities.
Carles
Joan
J
Department of Medical Oncology, Vall d'Hebron University Hospital, Barcelona, Spain.
Morales
Rafael
R
Perez
José Manuel
JM
Suárez
Cristina
C
Rodón
Jordi
J
Valverde
Claudia
C
D000911:Antibodies, Monoclonal / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000075202:Contraindications; D004791:Enzyme Inhibitors / Q000009:adverse effects; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced*; D009369:Neoplasms / Q000188:drug therapy*; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000150:complications; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D042461:Vascular Endothelial Growth Factor A; D066246:ErbB Receptors